-
Anavex Life Sciences Says Rett Syndrome Trial Meets Primary & Secondary Goals
Tuesday, February 1, 2022 - 10:38am | 369Read More...Anavex Life Sciences Corp (NASDAQ: AVXL) reported topline data from the Phase 3 AVATAR trial of ANAVEX2-73 (blarcamesine) in adult female patients with Rett syndrome. The data demonstrated a statistically significant improvement over placebo for the primary efficacy endpoint and all the...
-
Acadia Pharma Jumps After Rett Syndrome Candidate Aces Phase 3 Study
Tuesday, December 7, 2021 - 8:00am | 291Read More...Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced topline results from Phase 3 Lavender study of trofinetide in Rett syndrome. The 12-week study demonstrated a statistically significant improvement over placebo for both co-primary endpoints. Rett syndrome is a rare genetic...
-
Taysha Gene Therapies' Rett Syndrome Candidate Shows Encouraging Action In Animal Studies, Human Trial To Start By 2021
Monday, May 10, 2021 - 1:17pm | 342Read More...Taysha Gene Therapies Inc (NASDAQ: TSHA) has announced the online publication of new preclinical data for TSHA-102 in Rett syndrome. The data will be included in the May edition of Brain, a peer-reviewed neurological science journal. Rett syndrome is a rare, severe neurological...
-
Biotech Stock On The Radar: Anavex, A Neurology-Focused Precision Medicine Company
Wednesday, September 25, 2019 - 5:32pm | 1406Read More...The European Rett Syndrome Conference gets underway Friday in Finland. Among the presenters: a New York-based micro-cap biotech that has an investigational asset to treat Rett syndrome in its pipeline. Anavex Life Sciences Corp (NASDAQ: AVXL), founded in 2006, is a biotech that focuses...
-
Anavex Life Sciences Erases 5% Gain, Company Released Of Encouraging Preclinical Results
Thursday, February 25, 2016 - 1:58pm | 248Read More...Shares of Anavex Life Sciences Corp. (NASDAQ: AVXL), a clinical-stage biopharmaceutical company that focuses on therapies for Alzheimer's Disease, were trading higher by more than 5 percent Thursday morning - only to give up gains and trade flat by the afternoon. Investors and traders were...
